pf-05231023
Recombinant proteinexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01285518)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast growth factor 21Supplementation
FGF21 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-05231023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01923389 | Phase 1 | Sep 1, 2013 | Pfizer |
| NCT01673178 | Phase 1 | Oct 1, 2012 | Pfizer |
| NCT01396187 | Phase 1 | Jul 1, 2011 | Pfizer |
| NCT01285518 | Phase 1 | Feb 1, 2011 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 1 | 2011 |
1 organizations
Page 1 / 1